How Long Can You Live With Kidney and Heart Failure?

Survival with combined heart and kidney failure varies enormously depending on how advanced each organ’s disease is, but the combination consistently shortens life compared to either condition alone. A person with mild kidney impairment and stable heart failure may live for many years on medication, while someone with severe failure of both organs who requires dialysis faces a median survival measured in months. One study of heart failure patients who progressed to dialysis-dependent kidney failure found a median survival of just 95 days, though mean survival stretched to about 14 months because some patients lived much longer than others.¹ The range is wide because so many variables are in play, from age and the underlying cause of disease to whether kidney function can be partially restored.

Why Heart Failure and Kidney Failure Feed Each Other

The heart and kidneys depend on each other in ways that create a vicious cycle when either one starts to fail. A weakened heart pumps less blood to the kidneys, reducing their ability to filter waste and regulate fluid. At the same time, failing kidneys retain fluid and salt, which increases the volume of blood the heart has to move, stressing it further. This back-and-forth damage loop is what clinicians call cardiorenal syndrome, and it is associated with sharply worse outcomes than either heart failure or kidney disease in isolation.² The relationship is not a simple one-way street: heart injury can trigger kidney decline, kidney injury can accelerate heart disease, and a sudden crisis in either organ can drag the other down acutely.³

One mechanism that deserves more attention than it usually gets is venous congestion. The traditional explanation centers on the heart not pumping enough blood forward, but research increasingly points to backward pressure as the bigger culprit for kidney damage. When the right side of the heart fails, blood backs up in the veins, raising the pressure inside the kidneys. Because the kidney sits inside a tight capsule with little room to expand, even modest increases in venous pressure compress the tiny vessels and tubules that do the organ’s filtering work.⁴ In patients hospitalized with advanced heart failure, those whose central venous pressure stayed elevated were far more likely to see their kidneys worsen, and this held true regardless of blood pressure, cardiac output, or how much kidney function they had at baseline.⁵

How Kidney Function Changes the Survival Numbers

The clearest way to understand the prognosis is as a sliding scale: the worse your kidneys are, the shorter survival tends to be, at every stage of heart failure. A large registry study of heart failure patients found that mortality rose steadily as kidney filtration rates dropped. Compared to patients with normal kidney function, those with moderately reduced function had modestly higher death rates, while those with the most severe kidney impairment faced roughly triple the risk of dying.⁶ That gradient persisted even after accounting for age, diabetes, the severity of heart failure symptoms, and the medications patients were taking.

When both organs deteriorate to the point that a patient needs dialysis, the picture becomes much grimmer. In the study that reported a 95-day median survival for heart failure patients starting dialysis, none of the usual markers doctors look at (ejection fraction, inflammatory markers, nutritional status) reliably predicted who would live longer. The only factors linked to better outcomes were younger age and recovery of some kidney function off dialysis.¹ A separate Australian and New Zealand study of patients hospitalized for acute heart failure confirmed that dialysis or renal failure was among the strongest non-cancer predictors of reduced long-term survival.⁷

Acute Crises and Their Lasting Impact

Not all combined organ failure develops slowly. Sometimes a sudden heart failure flare-up causes the kidneys to shut down acutely, a pattern known as cardiorenal syndrome type 1. This acute-on-acute scenario carries an especially high toll. In one cohort, patients with true acute kidney injury during a heart failure hospitalization had a one-year mortality rate of about 25%, compared to roughly 13% in patients whose kidneys held steady. Their in-hospital mortality alone was around 10%, and they experienced cardiogenic shock and respiratory failure at much higher rates than other groups.⁸ When the acute kidney injury is severe, the prognosis worsens dramatically; in-hospital mortality for the most serious grade of acute kidney injury during heart failure decompensation has been reported around 35 to 49%.⁹

Kidney function also tends to decline faster in the year before and after a heart failure hospitalization. One study tracking kidney trajectories found that the rate of kidney function loss roughly tripled during the year surrounding a heart failure event, compared to the slower baseline decline seen in the years before and after that critical window.¹⁰ Surviving the acute crisis matters, but so does recognizing that each hospitalization accelerates the long-term trajectory of kidney disease.

Additional Comorbidities Stack the Odds

Heart failure and kidney disease rarely travel alone. Diabetes, obesity, and metabolic disorders often coexist, and each additional condition shortens survival further. A study of patients hospitalized with acute heart failure found that those who had all three overlapping conditions (cardiovascular disease, kidney disease, and metabolic dysfunction) nearly doubled their risk of a major adverse cardiovascular event within one year and had similarly elevated risks of death and rehospitalization compared to patients with fewer overlapping problems.¹¹

Anemia is another common and often underappreciated complication. When the kidneys fail, they produce less erythropoietin, the hormone that drives red blood cell production. The resulting anemia reduces oxygen delivery to tissues, including to the already-stressed heart muscle, and worsens both conditions. This triangle of heart failure, kidney disease, and anemia is sometimes called cardiorenal anemia syndrome, and its presence is linked to higher rates of hospitalization and death.¹² ¹³ Managing anemia does not always translate into clear survival gains, but it tends to improve symptoms and exercise tolerance.

Medications That Can Buy Time

Several drug classes can slow the decline of both organs, though managing them gets trickier as kidney function worsens. Drugs that block the renin-angiotensin-aldosterone system (commonly known as ACE inhibitors, ARBs, and certain aldosterone blockers) are cornerstones of heart failure treatment and also protect the kidneys. The catch is that these drugs can raise potassium levels, and failing kidneys are already bad at clearing potassium. High potassium is itself dangerous for the heart. Yet discontinuing these drugs because of potassium concerns also raises the risk of cardiovascular events, hospitalization, and death.¹⁴ This creates a genuine dilemma. Real-world data suggest that when doctors reduce or stop these medications to manage potassium, patients fare worse in the long run.¹⁵ The general consensus is that the benefits usually outweigh the risks as long as potassium levels are closely monitored.¹⁶

A newer drug class, the non-steroidal mineralocorticoid receptor antagonists like finerenone, has shown promise specifically in patients who have both conditions alongside type 2 diabetes. In a large pooled analysis, finerenone reduced all-cause death by about 9%, cut heart failure hospitalizations by roughly 17%, and lowered the risk of a composite kidney outcome by about 20% over a median follow-up of nearly three years.¹⁷ A separate trial in patients with heart failure and preserved or mildly reduced pumping function (not limited to diabetics) showed that finerenone reduced total heart failure events by about 18%, though it did come with an increased risk of high potassium.¹⁸ These are meaningful reductions, but they are not cures. They extend and improve life at the margins, which matters when the baseline outlook is poor.

When Diuretics Stop Working

Diuretics are the main tool for removing excess fluid, and most people with heart failure take them daily. But as kidney function deteriorates, these drugs become progressively less effective, a problem called diuretic resistance. The reasons are layered: loop diuretics have a short window of action, and between doses the kidneys actively reabsorb the sodium that was just expelled. Failing kidneys compound this by reducing drug delivery to the site where diuretics actually work and by activating hormonal systems that promote salt retention.¹⁹

When standard doses of a single diuretic stop controlling fluid overload, doctors often turn to combination therapy: adding a second or third type of diuretic that blocks sodium reabsorption at a different point along the kidney’s filtering system.²⁰ This can work for a while, but progressive diuretic resistance is often a sign that the cardiorenal syndrome is advancing to a stage where dialysis or ultrafiltration may become necessary to manage fluid.

Dialysis With Heart Failure

For patients whose kidneys have failed to the point where they can no longer clear waste or manage fluid, dialysis becomes a question of when and how rather than whether. Heart failure adds significant complexity. Standard hemodialysis sessions remove large volumes of fluid over just a few hours, which can cause dangerous drops in blood pressure, particularly in a weak heart. Peritoneal dialysis, which uses the lining of the abdomen to filter blood continuously, tends to be gentler because it removes fluid more slowly. Observational data suggest that peritoneal dialysis is well tolerated in heart failure patients with reduced pumping function and can improve symptoms and functional status.²¹

As for which method leads to longer survival, the evidence is mixed. In one real-world study, median survival was about 13 months with peritoneal dialysis and about 20 months with hemodialysis, but after adjusting for the fact that sicker patients tend to be started on peritoneal dialysis, the mortality difference was no longer statistically significant.²² A comparative review reached a similar conclusion: peritoneal dialysis may reduce hospitalizations and seems to improve heart function in some patients, but no definitive survival advantage has been established over hemodialysis for this population.²³ More frequent or longer hemodialysis sessions, which remove fluid at a gentler pace, are another option that may bridge the gap.

Mechanical Heart Support and Transplantation

For patients with severe heart failure, a left ventricular assist device (LVAD) can take over much of the heart’s pumping work. One of the encouraging findings is that kidney function often improves after an LVAD is implanted, because the device restores blood flow to the kidneys. A multicenter study found that kidney filtration rates improved across all stages of pre-existing kidney disease after LVAD placement, and patients who showed early kidney improvement had higher survival rates (roughly 69%) compared to those who did not (about 56%).²⁴ That improvement tends to fade over time as the kidneys settle back toward their baseline, but the initial recovery can be enough to avoid or delay dialysis.

When both organs are beyond repair, simultaneous heart and kidney transplantation is an option for a small number of patients. A meta-analysis of transplant outcomes reported overall survival of about 95% at 30 days, 81% at one year, and 71% at five years.²⁵ These numbers are reasonably close to what is seen with heart transplantation alone, suggesting that the kidney graft does not dramatically worsen outcomes.²⁶ However, access to dual-organ transplantation is extremely limited by donor availability, and changes to organ allocation policies have complicated outcomes. Under a newer U.S. allocation policy, one-year survival after combined heart-kidney transplant dropped from about 91% to 85%, likely because sicker patients are now prioritized for hearts, leading to more complex surgical cases.²⁷

Choosing Conservative Management

Not every patient with advanced kidney and heart failure wants or is a candidate for dialysis. For older adults, especially those with multiple other serious conditions, conservative (non-dialytic) management is a legitimate path. A systematic review found that conservative management of end-stage kidney disease resulted in median survival of at least six months, with individual study estimates ranging from about 6 to 23 months.²⁸ The review also noted that any survival advantage dialysis might offer shrinks considerably in the presence of significant comorbidities, especially ischemic heart disease. For patients aged 80 and older, the evidence is genuinely ambiguous about whether dialysis extends life at all compared to supportive care.²⁹

Quality of life enters the equation heavily here. Patients managed conservatively report a high symptom burden, but preliminary studies suggest their overall quality of life is similar to that of age-matched dialysis patients, in part because they avoid the physical toll and time burden of dialysis sessions. People who decline dialysis can live for months to years with appropriate supportive care, and integrating palliative care early helps manage symptoms like breathlessness, fatigue, nausea, and pain.²⁸ Advance care planning is especially important for cardiorenal patients because the disease trajectory is unpredictable: a person may be stable for months and then decline rapidly after a single hospitalization.³⁰

Symptom Trajectories and What to Watch For

One of the frustrating aspects of cardiorenal disease is how variable the symptom trajectory can be. A study following over 3,000 adults with chronic kidney disease tracked heart-failure-type symptoms over time and identified five distinct patterns. The largest group, about 42%, remained stable with minimal symptoms. Another 36% had mild but steady symptoms. About 16% had persistently significant symptoms. A smaller group, around 5%, experienced substantial worsening over time, and a tiny fraction actually improved.³¹ The practical takeaway is that a diagnosis of combined heart and kidney failure does not automatically mean a steady downhill course. Many patients remain stable for extended periods, and knowing which trajectory group you are in can help shape realistic expectations.

Blood tests for certain biomarkers can help predict what is coming. Elevated levels of BNP (a hormone released by stressed heart muscle) and cardiac troponin (a protein that leaks from damaged heart cells) are consistently linked to worse outcomes in patients with both conditions.³² These markers predicted death and hospitalization even after adjusting for how much kidney function a patient had lost, which means they add information beyond what the kidney numbers alone can tell you.³³

Emerging Risk Prediction Tools

Predicting how long someone will live with both conditions has always been difficult because so many factors interact. Newer machine-learning models are being developed to sort through these variables more effectively than traditional risk scores. One validated model built from clinical trial data used seven inputs, including age, blood pressure, and a set of blood biomarkers, and achieved strong discrimination between patients at low, medium, and high risk of combined heart and kidney events. Patients classified as low risk had a 94% chance of not experiencing the composite outcome, while those classified as high risk had a 58% chance of experiencing it.³⁴ A broader review of machine-learning approaches in heart failure survival prediction found that these algorithms consistently outperformed older statistical models and could identify high-risk patients earlier, potentially allowing doctors to intervene sooner.³⁵ These tools are not yet routinely used at the bedside, but they represent where the field is heading: individualized risk estimates rather than population averages, built from the kind of complex data that no simple equation can capture.